Mednax Inc (MD)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) ratio for Mednax Inc is not provided in the data for the period ranging from March 31, 2020, to December 31, 2024. This means that the DSO figure, which measures how long it takes for a company to collect its accounts receivable, is not available for analysis.
The DSO ratio is a crucial metric in assessing a company's efficiency in collecting payments from its customers. A lower DSO indicates that the company is collecting payments quickly, which is generally favorable as it reflects strong cash flow management and efficient credit control. On the other hand, a higher DSO may suggest potential issues with collections, aging accounts receivable, or lenient credit policies.
Without the specific DSO figures for Mednax Inc, it is challenging to evaluate the company's effectiveness in managing its accounts receivable and liquidity position over the specified time frame. Therefore, further data or information would be required to conduct a detailed analysis of Mednax Inc's DSO ratio and its implications for the company's financial health and operational efficiency.
Peer comparison
Dec 31, 2024